Company
Who we are
What we do
Investor relations
News & key figures
Investor presentation
Xlife dates
ESG
Projects
Technology Platforms
Biotech and Therapies
Medical Technology
Artificial Intelligence
Contact
DE
Collaborative
Analyst coverage
Institute
Analyst
Target price
Report
Intron Health Research
Dominic Rose
47 CHF
view
Baader Bank
Amandeep Goyal
81 CHF
view
Stifel
Daniel Jelovcan
68 CHF
view
News
Press Releases
19.12.24
Xlife Sciences AG Publishes 2023 ESG Report: A Continued Commitment to Sustainable Innovation
28.6.24
Xlife Sciences AG: Successful General Assembly and New Trading Hours on the Sparks Segment of SIX
26.6.24
Xlife Sciences AG Reports Success in Liver Diagnostics – x-nuclear diagnostics GmbH Achieves Market Readiness
Archive
Ad hoc News
16.12.2024
Xlife Sciences AG Announces the Intended Listing of VERAXA Biotech AG on the NASDAQ Stock Exchange in the 2025 Fiscal Year
21.11.2024
Xlife Sciences AG Announces the listing of FUSE-AI GmbH on the London Stock Exchange in the First Half of 2025
30.9.2024
Xlife Sciences AG enables international co-investors to enter the stock and is planning a dual listing on the London Stock Exchange Group (LSEG)
Archive
Downloads
Financial Reports
September 19, 2024
Half-Year Report 2024
April 30, 2024
Valuation Report 2023
April 23, 2024
Annual Report 2023
September 21, 2023
Half-Year Report 2023
April 27, 2023
Valuation Report 2022
April 20, 2023
Annual Report 2022
September 28, 2022
Half-Year Report 2022
May 9, 2022
Valuation Report 2021
April 29, 2022
Annual Report 2021
February 8, 2022
Interim financial statement Q3 2021 (only in german)
August 5, 2021
Semi-Annual Report 2021
Half-year results (only available in German)
May 29, 2020
Annual statement 2020
Sign up for our media releases